Asset profile
Zenkuda · Kodiak Sciences (KOD)
- Indication
- wet age-related macular degeneration
- Also known as
- tarcocimab tedromer, KSI-501, tabirafusp alfa tedromer, KSI-301
Company
KODKodiak Sciences
KODKodiak SciencesKodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprieta…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06270836 | Phase 3 | Completed | Feb 13, 2026 | 255 | 38 of 39 sites in the United States |
| NCT06556368 | Phase 3 | Active, not recruiting | Aug 1, 2026 | 675 | 71 of 72 sites in the United States |
More from Kodiak Sciences
Other drugs and candidates from the same company tracked in this sector.